Clinical outcomes following PD-1 inhibitor elective discontinuation in cutaneous squamous cell carcinoma: exploring treatment de-escalation
Our findings advocate for a more tailored approach to the duration of PD-1 inhibitor therapy in cSCC, potentially reducing burdens of overtreatment. Future studies regarding establishing robust predictors for safe treatment discontinuation are required to enhance decision-making in clinical practice.
Authors
- Nethanel Asher (ORCID: https://orcid.org/0000-0002-4094-8045)
- Eyal Yosefof (ORCID: https://orcid.org/0000-0001-8211-9774)
- Gal Markel
- Daniel Hendler (ORCID: https://orcid.org/0000-0002-3305-1328)
- Itamar Averbuch (ORCID: https://orcid.org/0000-0003-1784-4528)
- Noga Kurman (ORCID: https://orcid.org/0009-0003-3078-6868)
- Nofar Edri
- Hadas Ditzian Kugler
Institutions
- Tel Aviv University (IL)
- Rabin Medical Center (IL)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2025-07-05
- DOI
- https://doi.org/10.1007/s00262-025-04115-y
- Citations
- 1
- Primary Topic
- Nonmelanoma Skin Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.35